Single application of low-dose mycophenolate mofetil-OX7- Immunoliposomes ameliorates experimental mesangial proliferative glomerulonephritis

Journal of Pharmacology and Experimental Therapeutics

Volumn 337, Issue 2, 2011, Pages 411-422

  Suana, A J ^a   Tuffin, G ^b   Frey, B M ^a   Knudsen, L ^c   Muhlfeld C ^d   Rodder S ^a   Marti, Hans Peter ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF APPLIED SCIENCES AND ARTS NORTHWESTERN SWITZERLAND   (Switzerland)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CREATININE; IMMUNOLIPOSOME; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; THY 1.1 IMMUNOLIPOSOME; UNCLASSIFIED DRUG;

ALBUMINURIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CREATININE URINE LEVEL; DRUG EFFICACY; DRUG MIXTURE; DRUG RESPONSE; DRUG TARGETING; EXTRACELLULAR MATRIX; IMMUNOHISTOCHEMISTRY; MALE; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; MESANGIUM CELL; NONHUMAN; PRIORITY JOURNAL; RAT; RISK REDUCTION; STEREOLOGY;

ACTINS; ANIMALS; ANTIGENS, THY-1; APOPTOSIS; BIOTINYLATION; COLORING AGENTS; DRUG CARRIERS; EXTRACELLULAR MATRIX; GLOMERULONEPHRITIS, MEMBRANOPROLIFERATIVE; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY FUNCTION TESTS; LIPOSOMES; MALE; METHACRYLATES; MICROSCOPY, ELECTRON; MYCOPHENOLIC ACID; PARAFFIN EMBEDDING; POLYETHYLENE GLYCOLS; PROLIFERATING CELL NUCLEAR ANTIGEN; RATS; RATS, WISTAR; TISSUE EMBEDDING; TOLONIUM CHLORIDE;

EID: 79955014321     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.110.176222     Document Type: Article

References (41)

1. Allison AC and Eugui EM (1996) Purine metabolism and immunosuppressive effects of mycophenolate mofetil (MMF). Clin Transplant 10:77-84. (Pubitemid 26076435)
2. Azuma H, Binder J, Heemann U, Schmid C, Tullius SG, and Tilney NL (1995) Effects of RS61443 on functional and morphological changes in chronically rejecting rat kidney allografts. Transplantation 59:460-466.
3. Bertram JF (2001) Counting in the kidney. Kidney Int 59:792-796. (Pubitemid 32157946)
4. Bertram JF, Soosaipillai MC, Ricardo SD, and Ryan GB (1992) Total numbers of glomeruli and individual glomerular cell types in the normal rat kidney. Cell Tissue Res 270:37-45.
5. Chiara M, Menegatti E, Di Simone D, Davit A, Bellis D, Sferch D, De Rosa G, Giachino O, Sena LM, and Roccatello D (2005) Mycophenolate mofetil and roscovitine decrease cyclin expression and increase p27(kip1) expression in anti Thy1 mesangial proliferative nephritis. Clin Exp Immunol 139:225-235. (Pubitemid 40222840)
6. Comper WD, Jerums G, and Osicka TM (2004Differences in urinary albumin detected by four immunoassays and high-performance liquid chromatography. Clin Biochem 37:105-111. (Pubitemid 38077160)
7. Daniel C, Duffield J, Brunner T, Steinmann-Niggli K, Lods N, and Marti HP (2001) Matrix metalloproteinase inhibitors cause cell cycle arrest and apoptosis in glomerular mesangial cells. J Pharmacol Exp Ther 297:57-68. (Pubitemid 32242563)
8. Dillon JJ (2001) Treating IgA nephropathy. J Am Soc Nephrol 12:846-847. (Pubitemid 32246714)
9. Dubus I, Vendrely B, Christophe I, Labouyrie JP, Delmas Y, Bonnet J, and Combe C (2002) Mycophenolic acid antagonizes the activation of cultured human mesangial cells. Kidney Int 62:857-867. (Pubitemid 35316714)
10. Dufresne I, Désormeaux A, Bestman-Smith J, Gourde P, Tremblay MJ, and Bergeron MG (1999) Targeting lymph nodes with liposomes bearing anti-HLA-DR Fab' fragments. Biochim Biophys Acta 1421:284-294. (Pubitemid 29460669)
11. Falkenberg FW, Hengelage T, Krane M, Bartels I, Albrecht A, Holtmeier N, and Wüthrich M (1993) A simple and inexpensive high density dialysis tubing cell culture system for the in vitro production of monoclonal antibodies in high concentration. J Immunol Methods 165:193-206.
12. Floege J, Eng E, Lindner V, Alpers CE, Young BA, Reidy MA, and Johnson RJ (1992) Rat glomerular mesangial cells synthesize basic fibroblast growth factor. Release, upregulated synthesis, and mitogenicity in mesangial proliferative glomerulonephritis. J Clin Invest 90:2362-2369. (Pubitemid 23010054)
13. Floege J, Johnson RJ, Gordon K, Iida H, Pritzl P, Yoshimura A, Campbell C, Alpers CE, and Couser WG (1991) Increased synthesis of extracellular matrix in mesangial proliferative nephritis. Kidney Int 40:477-488.
14. Goren D, Horowitz AT, Tzemach D, Tarshish M, Zalipsky S, and Gabizon A (2000) Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug- resistance efflux pump. Clin Cancer Res 6:1949-1957. (Pubitemid 30305094)
15. Gundersen HJ (1978) Estimators of the number of objects per area unbiased by edge effects. Microsc Acta 81:107-117. (Pubitemid 9058313)
16. Gundersen HJ and Jensen EB (1987) The efficiency of systematic sampling in stereology and its prediction. J Microsc 147:229-263.
17. Guo M, Ricardo SD, Deane JA, Shi M, Cullen-McEwen L, and Bertram JF (2005) A stereological study of the renal glomerular vasculature in the db/db mouse model of diabetic nephropathy. J Anat 207:813-821. (Pubitemid 43019739)
18. Huwyler J, Wu D, and Pardridge WM (1996) Brain drug delivery of small molecules using immunoliposomes. Proc Natl Acad Sci USA 93:14164-14169. (Pubitemid 26424263)
19. Jefferson JA and Johnson RJ (1999) Experimental mesangial proliferative glomerulonephritis (the anti-Thy-1.1 model). J Nephrol 12:297-307. (Pubitemid 30014640)
20. Johnson RJ, Iida H, Alpers CE, Majesky MW, Schwartz SM, Pritzi P, Gordon K, and Gown AM (1991) Expression of smooth muscle cell phenotype by rat mesangial cells in immune complex nephritis. Alpha-smooth muscle actin is a marker of mesangial cell proliferation. J Clin Invest 87:847-858.
21. Krämer S, Loof T, Martini S, Rückert M, Wang Y, Böhler T, Shimizu F, Kawachi H, Neumayer HH, and Peters H (2005) Mycophenolate mofetil slows progression in anti-thy1-induced chronic renal fibrosis but is not additive to a high dose of enalapril. Am J Physiol Renal Physiol 289:F359-F368. (Pubitemid 41003665)
22. Lindmark R, Thorén-Tolling K, and Sjöquist J (1983) Binding of immunoglobulins to protein A and immunoglobulin levels in mammalian sera. J Immunol Methods 62:1-13. (Pubitemid 13036954)
23. Maes BD, Oyen R, Claes K, Evenepoel P, Kuypers D, Vanwalleghem J, Van Damme B, and Vanrenterghem YF (2004) Mycophenolate mofetil in IgA nephropathy: Results of a 3-year prospective placebo-controlled randomized study. Kidney Int 65:1842-1849. (Pubitemid 38591034)
24. Maruyama K, Holmberg E, Kennel SJ, Klibanov A, Torchilin VP, and Huang L (1990) Characterization of in vivo immunoliposome targeting to pulmonary endothelium. J Pharm Sci 79:978-984. (Pubitemid 20376189)
25. Nyengaard JR (1999) Stereologic methods and their application in kidney research. J Am Soc Nephrol 10:1100-1123. (Pubitemid 29203099)
26. Paul LC, Rennke HG, Milford EL, and Carpenter CB (1984) Thy-1.1 in glomeruli of rat kidneys. Kidney Int 25:771-777. (Pubitemid 14082183)
27. Pozzi C, Andrulli S, Del Vecchio L, Melis P, Fogazzi GB, Altieri P, Ponticelli C, and Locatelli F (2004) Corticosteroid effectiveness in IgA nephropathy: Long-term results of a randomized, controlled trial. J Am Soc Nephrol 15:157-163. (Pubitemid 38020707)
28. Sahin GM, Sahin S, Kantarci G, and Ergin H (2007) Mycophenolate mofetil treatment for therapy-resistant glomerulopathies. Nephrology 12:285-288. (Pubitemid 46718198)
29. ScherleW(1970) A simple method for volumetry of organs in quantitative stereology. Mikroskopie 26:57-60.
30. Sengoelge G, Perschl A, Ferrara I, Hörl WH, and Sunder-Plassmann G (2002) Surface antigens of human mesangial cells: Impact of growth surface or IL-1alpha. Tissue Antigens 60:383-395. (Pubitemid 36020795)
31. Steinmann-Niggli K, Ziswiler R, Küng M, and Marti HP (1998) Inhibition of matrix metalloproteinases attenuates anti-Thy1.1 nephritis. J Am Soc Nephrol 9:397-407.
32. Sterio DC (1984) The unbiased estimation of number and sizes of arbitrary particles using the disector. J Microsc 134:127-136. (Pubitemid 14121386)
33. Tang SC, Tang AW, Wong SS, Leung JC, Ho YW, and Lai KN (2010) Long-term study of mycophenolate mofetil treatment in IgA nephropathy. Kidney Int 77:543-549.
34. Torchilin VP (2005) Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 4:145-160. (Pubitemid 40282557)
35. Tuffin G, Huwyler J, Waelti E, Hammer C, and Marti HP (2008) Drug targeting using OX7-immunoliposomes: Correlation between Thy1.1 antigen expression and tissue distribution in the rat. J Drug Target 16:156-166. (Pubitemid 351266552)
36. Tuffin G, Waelti E, Huwyler J, Hammer C, and Marti HP (2005) Immunoliposome targeting to mesangial cells: A promising strategy for specific drug delivery to the kidney. J Am Soc Nephrol 16:3295-3305. (Pubitemid 46179334)
37. Vetterlein F, Mü hlfeld C, Cetegen C, Volkmann R, Schrader C, and Hellige G (2006) Redistribution of connexin43 in regional acute ischemic myocardium: Influence of ischemic preconditioning. Am J Physiol Heart Circ Physiol 291:H813-H8139.
38. Villarroel MC, Hidalgo M, and Jimeno A (2009) Mycophenolate mofetil: An update. Drugs Today 45:521-532.
39. Waelti E, Wegmann N, Schwaninger R, Wetterwald A, Wingenfeld C, Rothen- Rutishauser B, and Gimmi CD (2002) Targeting her-2/neu with anti-rat Neu virosomes for cancer therapy. Cancer Res 62:437-444. (Pubitemid 34106416)
40. Weibel ER and Knight BW (1964) A morphometric study on the thickness of the pulmonary air-blood barrier. J Cell Biol 21:367-396.
41. Ziswiler R, Steinmann-Niggli K, Kappeler A, Daniel C, and Marti HP (1998) Mycophenolic acid: A new approach to the therapy of experimental mesangial proliferative glomerulonephritis. J Am Soc Nephrol 9:2055-2066. (Pubitemid 28482153)